Medicine and Dentistry
Human Immunodeficiency Virus
100%
Microbicide
50%
Phase I Trials
20%
Pro 2000
20%
Nevirapine
20%
Clinical Trial
20%
Phase II Trials
10%
Intervention Trial
10%
Prevalence
10%
Vertical Transmission
10%
Biostatistics
10%
Human Immunodeficiency Virus Vaccine
10%
Post-Exposure Prophylaxis
10%
Infectious Disease Epidemiology
10%
Immunology
10%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Microbicide
50%
Phase I Trials
20%
Nevirapine
20%
Clinical Trial
20%
Pro 2000
20%
Prevalence
10%
Vertical Transmission
10%
Infection
10%
Phase II Trials
10%
Biostatistics
10%
Human Immunodeficiency Virus Vaccine
10%
Intervention Trial
10%
Agricultural and Biological Sciences
Human Immunodeficiency Virus
100%
Africans
27%
Nevirapine
18%
Focus Group
9%
Prevalence
9%